Skip to main content

Table 2 Comparison of three clinical scores between and within two groups at different follow-up time points

From: Clinical efficacy of cell-free fat extract and its effects on bone marrow edema in patients with early to mid-stage knee osteoarthritis: a clinical trial in comparison with hyaluronic acid

 

CEFFE group (n = 26)

HA group (n = 26)

P (intergroup)

VAS

3W

4.00 (3.00,5.00)*

3.50 (3.00,5.00)*

0.433

6W

2.50 (2.00,3.00)*a

3.00 (3.00,4.00)*

0.040

3 M

2.00(1.00,3.00)*ab

3.00 (3.00,5.00)*

0.001

6 M

1.00 (1.00,2.25)*ab

3.00 (2.75,5.25)*bc

0.000

P (within-group)

 < 0.001

 < 0.001

 

Group effect (Wald χ2, P)

6.376,0.012

  

Time effect (Wald χ2,P)

404.007, < 0.001

  

Interaction effect (Wald χ2,P)

27.533, < 0.001

  

WOMAC

3W

49.00 (39.50,55.00)*

46.50 (36.00, 55.25)*

0.790

6W

38.50 (32.75, 43.25)*a

45.50 (38.00,55.00)*

0.036

3 M

23.50 (22.00,48.00)*ab

44.00 (36.50,58.75)*

0.001

6 M

21.00 (17.75,46.50)*ab

44.50 (35.25,58.00)*

0.001

P (within-group)

 < 0.001

 < 0.001

 

Group effect (F, P)

5.145,0.023

  

Time effect (F,P)

213.962, < 0.001

  

Interaction effect (F,P)

22.630, < 0.001

  

LYSHOLM

3W

80.00 (72.00, 85.00)*

78.00 (74.75, 82.00)*

0.137

6W

80.00 (72.00, 85.00)*a

78.50(72.75,80.00)*

0.001

3 M

90.00(78.00,91.00)*ab

79.00(64.75,82.00)*

 < 0.001

6 M

90.00(80.25,92.00)*ab

79.00(62.50,82.75)*

 < 0.001

P (within-group)

 < 0.001

 < 0.001

 

Group effect (F, P)

13.915, < 0.001

  

Time effect (F,P)

172.084, < 0.001

  

Interaction effect (F,P)

16.418,0.003

  
  1. Data are provided as median (upper quartile, lower quartile); P (intergroup) of Mann–Whitney test; P (within-group) of the Friedman test
  2. CEFFE, cell-free fat extract; HA, hyaluronic acid; VAS, visual analogue scale; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index; 3W, 3 weeks post-treatment; 6W, 6 weeks post-treatment; 3 M, 3 months post-treatment; 6 M, 6 months post-treatment
  3. *abccomparisons of time points within the group using the Wilcoxon signed-rank test; *P < 0.05 compared to baseline; aP < 0.05 compared to 3 weeks post-treatment; bP < 0.05 compared to 6 weeks post-treatment; cP < 0.05 compared to 3 months post-treatment